As attorneys across the country fight over whether to consolidate litigation over the bladder infection medication Elmiron into a single federal court, a district judge in Pennsylvania has decided that claims seeking medical monitoring over the medication can’t be litigated as a national class action.
U.S. District Judge Wendy Beetlestone of the Eastern District of Pennsylvania granted a motion by Janssen Pharmaceuticals to strike all allegations of a proposed nationwide class action in the case Almond v. Janssen Pharmaceuticals.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]